The aim of this propensity-matched cohort study was to evaluate the impact of prenatal SSRI exposure and a history of maternal depression on neonatal brain volumes and white matter microstructure. SSRI-exposed neonates (n¼27) were matched to children of mothers with no history of depression or SSRI use (n¼54). Additionally, neonates of mothers with a history of depression, but no prenatal SSRI exposure (n¼ 41), were matched to children of mothers with no history of depression or SSRI use (n¼ 82). Structural magnetic resonance imaging and diffusion weighted imaging scans were acquired with a 3T Siemens Allegra scanner. Global tissue volumes were characterized using an automatic, atlas-moderated expectation maximization segmentation tool. Local differences in gray matter volumes were examined using deformation-based morphometry. Quantitative tractography was performed using an adaptation of the UNC-Utah NA-MIC DTI framework. SSRI-exposed neonates exhibited widespread changes in white matter microstructure compared to matched controls. Children exposed to a history of maternal depression but no SSRIs showed no significant differences in brain development compared to matched controls. No significant differences were found in global or regional tissue volumes. Additional research is needed to clarify whether SSRIs directly alter white matter development or whether this relationship is mediated by depressive symptoms during pregnancy.
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Introduction
Approximately 18% of pregnant women in the U. S. suffer from depression (Waters et al., 2014) . Untreated antenatal depression is associated with intense emotional distress, low fetal growth, preterm birth, neonatal complications, and conduct problems and antisocial behavior in offspring (Waters et al., 2014; Yonkers et al., 2009 ). While there is no definitive answer regarding optimal treatment for antenatal depression, the American Psychiatric Association and the American College of Obstetricians and Gynecologists provide algorithms for multiple scenarios that result in the initiation or maintenance of pharmacotherapy. Overall, approximately 13% of pregnant women report antidepressant use (Cooper et al., 2007) with selective serotonin reuptake inhibitors (SSRIs) being the most commonly prescribed class. Despite widespread use of SSRIs during pregnancy, effects on the fetus are not fully understood and are a source of concern for many pregnant women.
SSRIs are diffusible through the placenta and blood brain barrier and could potentially target the developing fetal brain (Velasquez et al., 2013) . During this early period of neurodevelopment, serotonin from maternal, placental, and fetal sources is involved in neuronal proliferation, migration, and synaptogenesis (Whitaker-Azmitia, 2005) . In rodents, exposure to SSRIs in the prenatal and/or early neonatal period disrupts dendritic organization and formation of thalamocortical afferents to the somatosensory cortex and results in aberrant axonal morphology, abnormal raphe circuitry, and altered 
